The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors-Global Market Insights and Sales Trends 2025
Synopsis
SGLT2 is a member of the sodium-glucose cotransporter family which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney.The growing global type-2 diabetes population promotes the growth of SGLT2 drugs.
The global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors in various end use industries. The expanding demands from the Hospital, Medical Research Institute and Other,, are propelling Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market. Invokana (Canagliflozin), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Jardiance (Empagliflozin) segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market, driven by demand from China, the second largest economy with some signs of stabilising, the Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors covered in this report include Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb and Kotobuki Pharmaceutical, etc.
The global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
AstraZeneca
Bristol Myers Squibb
Kotobuki Pharmaceutical
Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market, Segment by Type:
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market, by Application
Hospital
Medical Research Institute
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
SGLT2 is a member of the sodium-glucose cotransporter family which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney.The growing global type-2 diabetes population promotes the growth of SGLT2 drugs.
The global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors in various end use industries. The expanding demands from the Hospital, Medical Research Institute and Other,, are propelling Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market. Invokana (Canagliflozin), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Jardiance (Empagliflozin) segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market, driven by demand from China, the second largest economy with some signs of stabilising, the Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors covered in this report include Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb and Kotobuki Pharmaceutical, etc.
The global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
AstraZeneca
Bristol Myers Squibb
Kotobuki Pharmaceutical
Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market, Segment by Type:
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market, by Application
Hospital
Medical Research Institute
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Overview
1.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Overview
1.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Segment by Type
1.2.1 Invokana (Canagliflozin)
1.2.2 Jardiance (Empagliflozin)
1.2.3 Farxiga/Forxiga (Dapagliflozin)
1.2.4 Suglat (Ipragliflozin)
1.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size by Type
1.3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size Overview by Type (2018-2029)
1.3.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Historic Market Size Review by Type (2018-2023)
1.3.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Breakdown by Type (2018-2023)
1.4.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Breakdown by Type (2018-2023)
2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Competition by Company
2.1 Global Top Players by Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales (2018-2023)
2.2 Global Top Players by Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue (2018-2023)
2.3 Global Top Players by Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Price (2018-2023)
2.4 Global Top Manufacturers Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Competitive Situation and Trends
2.5.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors as of 2022)
2.7 Date of Key Manufacturers Enter into Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market
2.8 Key Manufacturers Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Status and Outlook by Region
3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Historic Market Size by Region
3.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Volume by Region (2018-2023)
3.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Value by Region (2018-2023)
3.2.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecasted Market Size by Region
3.3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Volume by Region (2024-2029)
3.3.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Value by Region (2024-2029)
3.3.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors by Application
4.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Segment by Application
4.1.1 Hospital
4.1.2 Medical Research Institute
4.1.3 Other
4.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size by Application
4.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size Overview by Application (2018-2029)
4.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Historic Market Size Review by Application (2018-2023)
4.2.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Breakdown by Application (2018-2023)
4.3.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Breakdown by Application (2018-2023)
5 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors by Country
5.1 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Historic Market Size by Country
5.1.1 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Volume by Country (2018-2023)
5.1.3 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Value by Country (2018-2023)
5.2 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecasted Market Size by Country
5.2.1 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Volume by Country (2024-2029)
5.2.2 North America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Value by Country (2024-2029)
6 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors by Country
6.1 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Historic Market Size by Country
6.1.1 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Volume by Country (2018-2023)
6.1.3 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Value by Country (2018-2023)
6.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecasted Market Size by Country
6.2.1 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Volume by Country (2024-2029)
6.2.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Value by Country (2024-2029)
7 Asia-Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors by Region
7.1 Asia-Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Value by Region (2024-2029)
8 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors by Country
8.1 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Historic Market Size by Country
8.1.1 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Volume by Country (2018-2023)
8.1.3 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Value by Country (2018-2023)
8.2 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecasted Market Size by Country
8.2.1 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Volume by Country (2024-2029)
8.2.2 Latin America Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Value by Country (2024-2029)
9 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors by Country
9.1 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Eli Lilly
10.1.1 Eli Lilly Company Information
10.1.2 Eli Lilly Introduction and Business Overview
10.1.3 Eli Lilly Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Eli Lilly Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Products Offered
10.1.5 Eli Lilly Recent Development
10.2 Janssen Pharmaceuticals
10.2.1 Janssen Pharmaceuticals Company Information
10.2.2 Janssen Pharmaceuticals Introduction and Business Overview
10.2.3 Janssen Pharmaceuticals Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Janssen Pharmaceuticals Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Products Offered
10.2.5 Janssen Pharmaceuticals Recent Development
10.3 Astellas
10.3.1 Astellas Company Information
10.3.2 Astellas Introduction and Business Overview
10.3.3 Astellas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Astellas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Products Offered
10.3.5 Astellas Recent Development
10.4 Boehringer Ingelheim
10.4.1 Boehringer Ingelheim Company Information
10.4.2 Boehringer Ingelheim Introduction and Business Overview
10.4.3 Boehringer Ingelheim Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Boehringer Ingelheim Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Products Offered
10.4.5 Boehringer Ingelheim Recent Development
10.5 AstraZeneca
10.5.1 AstraZeneca Company Information
10.5.2 AstraZeneca Introduction and Business Overview
10.5.3 AstraZeneca Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.5.4 AstraZeneca Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Products Offered
10.5.5 AstraZeneca Recent Development
10.6 Bristol Myers Squibb
10.6.1 Bristol Myers Squibb Company Information
10.6.2 Bristol Myers Squibb Introduction and Business Overview
10.6.3 Bristol Myers Squibb Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Bristol Myers Squibb Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Products Offered
10.6.5 Bristol Myers Squibb Recent Development
10.7 Kotobuki Pharmaceutical
10.7.1 Kotobuki Pharmaceutical Company Information
10.7.2 Kotobuki Pharmaceutical Introduction and Business Overview
10.7.3 Kotobuki Pharmaceutical Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Kotobuki Pharmaceutical Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Products Offered
10.7.5 Kotobuki Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Industrial Chain Analysis
11.4 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Dynamics
11.4.1 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Industry Trends
11.4.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Drivers
11.4.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Challenges
11.4.4 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Distributors
12.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
